Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Goes Online; Genomic Solutions Says It s on the Upswing; Cash In Canada for Gene Expression


Agilent Goes Online


During April and May, Agilent Technologies is holding online “E-seminars” for customers at its website The first one, “Flow Cytometric Studies Using a Microfluidic Based Lab-on-a-Chip System,” is taking place on April 18 at 10AM PST, and May 23 at 10AM PST. This seminar describes applications of Agilent’s lab-on-a-chip technology, which can handle several samples and offers automated data acquisition. Seminar No. 2, “Quality Control of Microarray Samples using the Agilent 2100 Bioanalyzer,” will be held April 24 at 10AM PST, and May 28 at 10AM PST. Seminar No. 3, “Microarray-Based Solutions for Gene Expression Anaylsis,” will be held May 1 at 10AM PST and June 5 at 10AM PST. This seminar will cover Agilent’s oligonucleotide and cDNA microarrays as well as the new Agilent scanner.


Genomic Solutions Says It’s on the Upswing


Genomic Solutions, the Ann Arbor, Mich., maker of microarray and proteomic instruments, said its first-quarter 2002 revenues would likely exceed $6.6 million, reflecting an upturn in its business after two disappointing quarters.

“During the first quarter of 2002, we completed the sale of more than 75 large units, defined as the sale of a unit priced at $25,000 or more,” Jeffrey Williams, the company’s president and CEO, said in a statement. Williams said this turnaround resulted from “strategic changes in marketing, sales, and distribution,” as well as its acquisition of Cartesian Technologies in December, and the exclusive licensing agreement with proteomic software company ProteoMetrics it completed in February.

The company’s fourth-quarter revenues totaled $4.4 million, compared with $5.5 million for the fourth quarter of 2000. Its third-quarter revenues went down to $3.6 million, compared with $5 million in the previous year’s quarter.

Last fall, Genomic Solutions sold its proteomics contract services business and announced plans to trim its workforce of 170 by 25 percent as well as to close a research and development and manufacturing facility in Lansing, Mich., in order to stem operating costs and preserve cash reserves, which had dwindled to $13.1 million by the end of 2001.

Now, the company said that it is focusing on achieving profitability and generating earnings during the year. “We are confident we will continue to grow by providing innovative solutions with our wide-ranging portfolio of quality instruments, consumables, and software,” Williams said.


Cash In Canada for Gene Expression

Genome Canada said last week it had been awarded C$35.5 million, or $22.3 million, bringing to C$111.5 million the total current round of national investment in Canadian genomics projects. These projects include a significant investment in gene expression profiling in many areas of the country.

For example, a C$5.9 million grant was awarded for a comprehensive atlas of gene expression in mouse development, C$5.3 million was awarded for C. elegans tissue-expression profiling. Also, C$5.5 million is going to a wide-ranging gene expression project that involves four universities, four hospitals, and two research institutes in Quebec, as well as the companies SignalGene, Phenogene Therapeutics, and Geneka Biotechnology.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.